PetCure Oncology Selects Varian Halcyon Treatment System to Expand Access to Cancer Care for Pets | Varian

{ "pageType": "news-article", "title": "PetCure Oncology Selects Varian Halcyon Treatment System to Expand Access to Cancer Care for Pets", "articleDate": "27 de July de 2017", "introText": "", "category": "Oncology" }

PetCure Oncology Selects Varian Halcyon Treatment System to Expand Access to Cancer Care for Pets

PALO ALTO, Calif., July 27, 2017 /PRNewswire/ -- According to the National Institutes of Health, an estimated six million dogs and six million cats are diagnosed with cancer each year in the US. Up to now the access to advanced treatments for these treasured family members has been limited. To increase veterinary access to the advanced cancer care already available in human oncology, Varian Medical Systems (NYSE: VAR) and PetCure Oncology today announced a strategic collaboration that will bring an unprecedented level of care to pets suffering from cancer.

The strategic collaboration includes the deployment of Varian's software suite, including the RapidPlan™ and ARIA® platforms, across PetCure Oncology's national network of veterinary cancer care centers. In addition, PetCure Oncology will acquire six Varian Halcyon treatment systems for use in select sites across the US, providing access to the latest in radiation therapy technology to pets.

PetCure plans to leverage the many features of Halcyon, including its reduced facilities requirements and ease-of-use, to expand the availability of high quality cancer care for animals.  PetCure is scheduled to install the first system in late-August 2017.

"PetCure understands the impact a pet's cancer diagnosis has on a family," said Scott Milligan, CEO of PetCure Oncology. "We are committed to delivering them the highest level of cancer care and support. This strategic partnership with Varian ensures that our network of veterinary radiation oncologists has direct access to the best available clinical resources."

"We are excited about this opportunity with PetCure and its ability to deliver high quality treatments to many more pets," said Chris Toth, president of Global Commercial and Field Operations at Varian. "The use of RapidPlan to leverage the knowledge of previous treatments across PetCure's network and project it to future cases is a game changer in veterinary radiation therapy."

For more information on Halcyon, visit www.varian.com/halcyon.

About Varian Medical Systems
Varian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,600 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

About PetCure Oncology

PetCure Oncology specializes in radiation oncology for pets, partnering with leading specialty animal hospitals around the country to collaboratively offer comprehensive cancer care. Two new sites are scheduled to open this summer in San Jose and Jacksonville, joining established centers in Pittsburgh (PA), Phoenix (AZ), Clifton (NJ), Milwaukee (WI) and Cincinnati (OH) in providing human-caliber cancer care to pets. To learn more about PetCure Oncology, visit PetCureOncology.com.

Press Contacts

Mark Plungy
Varian Medical Systems
+1 (650) 424-5630
mark.plungy@varian.com

Neil Madle
Varian Medical Systems
+44 7786 526068
neil.madle@varian.com

Jack Moore
PetCure Oncology
+1 (847) 420-5594
jmoore@petcureoncology.com

 

SOURCE Varian Medical Systems